Global Generic Injectables Market Report and Forecast 2023-2031
Global Generic Injectables Market Outlook:
The global generic injectables market value was USD 101.3 billion in 2022, driven by the increasing demand for affordable healthcare across the globe. The market size is anticipated to grow at a CAGR of 13% during the forecast period of 2023-2031 to achieve a value of USD 305.5 billion by 2031.
Introduction
Generic injectables refer to pharmaceutical products that are identical or bioequivalent to brand-name injectable drugs but are marketed under their generic names. These medications are typically administered via injection, either intravenously, intramuscularly, or subcutaneously. Generic injectables offer cost-effective alternatives to brand-name drugs, providing healthcare providers and patients with more affordable treatment options without compromising quality or safety.
Key Trends in the Generic Injectables Market
Some key trends involved in the generic injectables market are as follows:
Increasing Demand for Affordable Healthcare: The rising cost of healthcare has led to a growing demand for affordable treatment options, including generic injectables. Healthcare providers and payers are actively seeking cost-saving measures, and the use of generic injectables offers significant savings without compromising patient care.
Patent Expirations and Market Opportunities: The expiration of patents for several widely-used injectable drugs has opened doors for generic manufacturers to enter the market. This has led to increased competition, reduced prices, and expanded access to essential medications.
Government Initiatives and Regulatory Support: Governments worldwide are implementing policies and initiatives to promote the use of generic medications, including injectables. These efforts aim to increase access to affordable healthcare and reduce healthcare expenditure. Regulatory agencies also play a vital role by establishing guidelines and standards for the approval and quality assurance of generic injectables.
Technological Advancements in Manufacturing: Advancements in manufacturing technologies have improved the efficiency and quality of generic injectable production. Advanced manufacturing techniques, such as lyophilization and aseptic processing, ensure the stability, safety, and sterility of generic injectables.
Expansion of Therapeutic Areas: The range of therapeutic areas covered by generic injectables is expanding. While they have traditionally been associated with essential medications like antibiotics and analgesics, generic injectables are now available for a broader range of therapies, including oncology, critical care, cardiovascular, and neurology.
Collaboration and Partnerships: Collaboration between generic pharmaceutical companies, contract manufacturers, and healthcare providers is becoming increasingly common. Such partnerships aim to ensure a stable supply of quality generic injectables and improve patient access to affordable medications.
Rising Demand for Biologics and Biosimilars: The growing demand for biologic drugs has paved the way for the development of biosimilars, which are highly similar but not identical to the original biologic drugs. Biosimilar injectables offer cost savings and expanded treatment options, contributing to the evolving landscape of generic injectables.
Generic Injectables Market Segmentations
Market Breakup by Product Type
Monoclonal Antibodies
Immunoglobulin
Cytokines
Insulin
Peptide Hormones
Blood Factors
Vaccines
Chemotherapy Agents
Small Molecules Antibiotics
Others
Market Breakup by Molecule Type
Large Molecules
Small Molecules
Market Breakup by Application
Oncology
Infections Diseases
Diabetes
Blood Disorders
Hormonal Disorders
Musculoskeletal Disorders
CNS Diseases
Pain Management
Cardiovascular Diseases
Others
Market Breakup by Route of Administration
Intramuscular
Intravenous
Subcutaneous
Market Breakup by Distribution Channel
Drug Store
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Market Breakup by Region
North America
United States of America
Canada
Europe
United Kingdom
Germany
France
Italy
Others
Asia Pacific
China
Japan
India
ASEAN
Australia
Others
Latin America
Brazil
Argentina
Mexico
Others
Middle East and Africa
Saudi Arabia
United Arab Emirates
Nigeria
South Africa
Others
Generic Injectables Market Scenario
The market for generic injectables is a rapidly growing segment within the pharmaceutical industry. Generic injectables are cost-effective alternatives to brand-name injectable drugs, offering healthcare providers and patients more affordable treatment options without compromising quality or safety.
The market is driven by several factors, including the increasing demand for affordable healthcare solutions, the expiration of patents for widely-used injectable drugs, and government initiatives promoting the use of generic medications. Healthcare providers and payers are actively seeking cost-saving measures, and generic injectables provide significant savings without compromising patient care.
Overall, the market for generic injectables is driven by the increasing demand for affordable healthcare, patent expirations, government initiatives, technological advancements, therapeutic expansion, and collaboration. As the demand for cost-effective injectable medications continues to rise, the market for generic injectables is expected to grow, providing healthcare providers and patients with more accessible treatment options.
Generic Injectables Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Abbott
B.D.
Novartis AG
Pfizer Inc.
Baxter
Gerresheimer AG
Germany
AstraZeneca
Terumo Medical Corporation
Teva Pharmaceutical Industries Ltd.
Eli Lilly and Company
Schott AG
Sanofi
Johnson & Johnson Private Limited
Mylan N.V.
West Pharmaceutical Services, Inc.
SHL Medical AG
Insulet Corporation
E3D Elcam
Drug Delivery Devices
Ypsomed AG
AbbVie Inc.
Novo Nordisk A/S
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Generics Injectable Market Overview
- 3.1 Global Generics Injectable Market Historical Value (2016-2022)
- 3.2 Global Generics Injectable Market Forecast Value (2023-2031)
- 4 Global Generics Injectable Market Landscape
- 4.1 Global Generics Injectable Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Generics Injectable Product Landscape
- 4.2.1 Analysis by Product Type
- 4.2.2 Analysis by Applications
- 4.2.3 Analysis by Distribution Channel
- 5 Global Generics Injectable Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Generics Injectable Market Segmentation
- 6.1 Global Generics Injectable Market by Product Type
- 6.1.1 Market Overview
- 6.1.2 Monoclonal Antibodies
- 6.1.3 Immunoglobulin
- 6.1.4 Cytokines
- 6.1.5 Insulin
- 6.1.6 Peptide Hormones
- 6.1.7 Blood Factors
- 6.1.8 Vaccines
- 6.1.9 Chemotherapy Agents
- 6.1.10 Small Molecules Antibiotics
- 6.1.11 Others
- 6.2 Global Generics Injectable Market by Molecule Type
- 6.2.1 Market Overview
- 6.2.2 Large Molecules
- 6.2.3 Small Molecules
- 6.3 Global Generics Injectable Market by Application
- 6.3.1 Market Overview
- 6.3.2 Oncology
- 6.3.3 Infections Diseases
- 6.3.4 Diabetes
- 6.3.5 Blood Disorders
- 6.3.6 Hormonal Disorders
- 6.3.7 Musculoskeletal Disorders
- 6.3.8 CNS Diseases
- 6.3.9 Pain Management
- 6.3.10 Cardiovascular Diseases
- 6.3.11 Others
- 6.4 Global Generics Injectable Market by Route of Administration
- 6.4.1 Market Overview
- 6.4.2 Intramuscular
- 6.4.3 Intravenous
- 6.4.4 Subcutaneous
- 6.5 Global Generics Injectable Market by Distribution Channel
- 6.5.1 Market Overview
- 6.5.2 Drug Store
- 6.5.3 Hospital Pharmacies
- 6.5.4 Online Pharmacies
- 6.5.5 Retail Pharmacies
- 6.6 Global Generics Injectable Market by Region
- 6.6.1 Market Overview
- 6.6.2 North America
- 6.6.3 Europe
- 6.6.4 Asia Pacific
- 6.6.5 Latin America
- 6.6.6 Middle East and Africa
- 7 North America Generics Injectable Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Generics Injectable Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Generics Injectable Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Generics Injectable Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Generics Injectable Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Regulatory Framework
- 16.1 Regulatory Overview
- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 INDIA CDSCO
- 16.1.4 JAPAN PMDA
- 16.1.5 Others
- 17 Supplier Landscape
- 17.1 Abbott
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 B.D.
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Novartis AG
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Pfizer Inc.
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Baxter
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Gerresheimer AG
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Germany
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 AstraZeneca
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Terumo Medical Corporation
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 Teva Pharmaceutical Industries Ltd.
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Eli Lilly and Company
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Schott AG
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Sanofi
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 Johnson & Johnson Private Limited
- 17.14.1 Financial Analysis
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisitions
- 17.14.5 Certifications
- 17.15 Mylan N.V.
- 17.15.1 Financial Analysis
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisitions
- 17.15.5 Certifications
- 17.16 West Pharmaceutical Services, Inc.
- 17.16.1 Financial Analysis
- 17.16.2 Product Portfolio
- 17.16.3 Demographic Reach and Achievements
- 17.16.4 Mergers and Acquisitions
- 17.16.5 Certifications
- 17.17 SHL Medical AG
- 17.17.1 Financial Analysis
- 17.17.2 Product Portfolio
- 17.17.3 Demographic Reach and Achievements
- 17.17.4 Mergers and Acquisitions
- 17.17.5 Certifications
- 17.18 Insulet Corporation
- 17.18.1 Financial Analysis
- 17.18.2 Product Portfolio
- 17.18.3 Demographic Reach and Achievements
- 17.18.4 Mergers and Acquisitions
- 17.18.5 Certifications
- 17.19 E3D Elcam
- 17.19.1 Financial Analysis
- 17.19.2 Product Portfolio
- 17.19.3 Demographic Reach and Achievements
- 17.19.4 Mergers and Acquisitions
- 17.19.5 Certifications
- 17.20 Drug Delivery Devices
- 17.20.1 Financial Analysis
- 17.20.2 Product Portfolio
- 17.20.3 Demographic Reach and Achievements
- 17.20.4 Mergers and Acquisitions
- 17.20.5 Certifications
- 17.21 Ypsomed AG
- 17.21.1 Financial Analysis
- 17.21.2 Product Portfolio
- 17.21.3 Demographic Reach and Achievements
- 17.21.4 Mergers and Acquisitions
- 17.21.5 Certifications
- 17.22 AbbVie Inc.
- 17.22.1 Financial Analysis
- 17.22.2 Product Portfolio
- 17.22.3 Demographic Reach and Achievements
- 17.22.4 Mergers and Acquisitions
- 17.22.5 Certifications
- 17.23 Novo Nordisk A/S
- 17.23.1 Financial Analysis
- 17.23.2 Product Portfolio
- 17.23.3 Demographic Reach and Achievements
- 17.23.4 Mergers and Acquisitions
- 17.23.5 Certifications
- 18 Global Generics Injectable Market- Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Pricing Models and Strategies (Additional Insight)
- 21.1 Overview
- 21.2 Cost Model
- 21.2.1 Manufacturing Cost Analysis
- 21.2.2 Procurement Cost Analysis
- 21.2.3 Clinical Trial Cost Factors
- 21.3 Pricing Strategies
- 21.3.1 Competitor Pricing Analysis
- 21.3.2 Key Assessment of Product Attributes
- 21.3.3 Pricing Benchmark
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook